Novatium Therapeutics

Novatium Therapeutics is a biotechnology company focused on developing a new class of precision medicines that target RNA-binding proteins (RBPs) to treat neurodegenerative diseases and cancer. The company leverages a proprietary platform to identify and modulate specific RBP-RNA interactions that are central to disease pathology, particularly in conditions characterized by protein misfolding and dysregulated RNA processing. Novatium's lead research efforts are directed toward amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), with a focus on correcting the pathological behavior of TDP-43. Headquartered in Cambridge, Massachusetts, the company is backed by prominent life science investors and aims to restore cellular homeostasis through small molecule intervention.